Literature DB >> 10223544

Hepatitis C genotypes and subtypes in Saudi Arabia.

O A Shobokshi1, F E Serebour, L Skakni, Y H Al-Saffy, M N Ahdal.   

Abstract

Hepatitis C virus (HCV) genotypes are diverse geographically. Infectivity, pathogenicity, and sustained response to treatment may be influenced by HCV genotypes/subtypes. This study examined the relative distribution of hepatitis C genotypes and subtypes among isolates from 84 individuals with chronic active hepatitis (CAH), 39 haemodialysis patients, and 31 intravenous drug addicts, of Saudi Arabian origin. Reverse transcription-polymerase chain reaction (RT-PCR) using specific primers from the 5'-UTR was performed and amplified products were genotyped/subtyped using a commercial reverse phase hybridisation technique (Innolipa HCV 11, Innogenetics, Belgium). Seventy-four percent of the CAH patients were found to be genotype 4 (4c/4d: 33%; 4h: 14%; 4e: 7%; 4: 20%) but other subtypes such as 1b: 14%, 2b: 4%, 3a: 5%, 5a: 1%, and 6a: 1%, were also detected. A history of blood transfusion was disclosed in only 10% of the CAH group. The pattern among haemodialysis patients was as follows: genotype 4: 49% (4h: 13%; 4: 36% ); 1a: 33%, 1: 3%; 1b: 10%; and 5a: 5%. The intravenous drug addict group showed 39% subtype 1b, but other subtypes such as 9% for 1a; 3% for 2a; 36% for 4; 3% for 5a; and 9% for 3a were seen. It is concluded that genotype 4 is predominant among our HCV isolates from CAH patients but subtype 1a and 1b have emerged among our haemodialysis and intravenous drug addict cases, respectively. A significant relationship between the viral genotype and the source of infection has emerged among Saudi groups at high risk for hepatitis C virus.

Entities:  

Mesh:

Year:  1999        PMID: 10223544

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  29 in total

1.  Three cases of infection with hepatitis C virus genotype 5 among Brazilian hepatitis patients.

Authors:  José Eduardo Levi; Deise Tihe Takaoka; Regina Helena Garrini; Roberta Maria Fachini; Roberto Focaccia; Edgar De Bortholi Santos; Heloisa Pedrosa Mitre; João Silva De Mendonça; Norma De Paula Cavalheiro; Antonio Alci Barone; Silvano Wendel
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

2.  Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report.

Authors:  M D Aljurf; S Z Zaidi; H El Solh; F Hussain; A Ghavamzadeh; H K Mahmoud; T Shamsi; T Ben Othman; M M Sarhan; D Dennison; A Ibrahim; S Benchekroun; N Chaudhri; B Labar; M Horowitz; D Niederwieser; A Gratwohl
Journal:  Bone Marrow Transplant       Date:  2008-12-01       Impact factor: 5.483

3.  Hepatitis C virus genotype 5 in southern belgium: epidemiological characteristics and response to therapy.

Authors:  Jean Delwaide; Christiane Gerard; Catherine Reenaers; Dolores Vaira; Boris Bastens; Christian Bataille; Benoit Servais; Bernard Maes; Jacques Belaiche; Groupe Liegeois D'etudes Des Virus Hepatotropes
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

Review 4.  Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.

Authors:  Vasilios Papastergiou; Stylianos Karatapanis
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

5.  Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy.

Authors:  S J Polyak; K S Khabar; M Rezeiq; D R Gretch
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: a tertiary care center experience.

Authors:  Hamad Al Ashgar; Mohammed Q Khan; Ahmed Helmy; Khalid Al Swat; Abdullah Al Shehri; Abdalla Al Kalbani; Musthafa Peedikayel; Khalid Al Kahtani; Mohammed Al Quaiz; Mohammed Rezeig; Ingvar Kagevi; Mohammed Al Fadda
Journal:  Saudi J Gastroenterol       Date:  2008-04       Impact factor: 2.485

7.  Hepatitis C treatment: trial by design.

Authors:  Khalid I Bzeizi
Journal:  Saudi J Gastroenterol       Date:  2008-04       Impact factor: 2.485

8.  Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population.

Authors:  Yaser Dahlan; Hafiz-Mughees Ather; Majid Al-ahmadi; Faisal Batwa; Waleed Al-hamoudi
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

Review 9.  Epidemiology and treatment of hepatitis C genotypes 5 and 6.

Authors:  Khalid Al Naamani; Siham Al Sinani; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2013-01       Impact factor: 3.522

10.  Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Authors:  Hamad Al Ashgar; Ahmed Helmy; Mohamed Q Khan; Khalid Al Kahtani; Mohammed Al Quaiz; Mohammed Rezeig; Ingvar Kagevi; Abdullah Alshehri; Abdullah Al Kalbani; Khalid Al Swat; Salim Dahab; Naser Elkum; Mohammed Al Fadda
Journal:  Ann Saudi Med       Date:  2009 Jan-Feb       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.